Patients with multiple myeloma treated with idecabtagene vicleucel, known as “ide-cel,” a chimeric antigen receptor (CAR) T-cell therapy, had no difference in overall survival outcomes regardless of race and ethnicity, according to a study published in Blood Advances.
Screening debate: Insufficient evidence to support lung cancer screening for non-smokers
Lung cancer remains the leading cause of cancer-related deaths worldwide. Detecting this disease in its early stages significantly improves survival rates, making low-dose CT screening
August 5, 2024